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Abstract
Diagnosing candidaemia remains difﬁcult despite the development of new diagnostics. We report a direct comparison of three different
blood-culture systems and four indirect tests. One hundred and fourteen episodes either with haematological disease and fever despite
antibacterials, or with documented invasive candidiasis, were enrolled prospectively. Clinical, para-clinical information and surveillance
cultures were obtained. Blood culture was performed using conventional blood-culture bottles, mycosis bottles, and the Isolator 10 lysis
centrifugation system. Serum D-arabinitol/L-arabinitol (DA/LA) ratios were determined by gas chromatography mass spectrometry.
Antigen, mannan-antigen (Ag) and anti-mannan antibody (Ab) were detected by CandTec, Platelia Candida Ag ELISA and Candida AB/
AC/AK kits, respectively. Episodes were classiﬁed as proven (n = 24), probable (n = 14), possible (n = 52) or unlikely (n = 24) invasive
candidiasis. Candidaemia involved C. albicans (17), C. albicans + C. glabrata (3), C. tropicalis (1) and yeast (1). Mycosis bottles yielded two
additional positives and the conventional blood culture yielded one positive not identiﬁed by other blood-culture methods. Considering
proven and unlikely episodes, respectively, sensitivity and speciﬁcity were as follows: mannan-Ag and/or anti-mannan Ab: 83.3%, 78.3%;
DA/LA ratio: 41.7%, 86.4%; and CandTec Candida Ag: 66.6%, 70.8%. Lowering the cut-off values to mannan-Ag 0.10 ng/mL and
anti-mannan Ab 4 AU/mL, the values were: 100%, 73.9%. Applying the DA/LA ratio to only patients with haematological neutropenia
the values were: 75%, 90.5%. Fungal blood culture allowed slightly improved detection of candidaemia. The best indirect test per-
formance was obtained from combined mannan-Ag and anti-mannan Ab detection, especially with lower cut-offs. DA/LA ratio appears
to be useful in the context of haematological neutropenia.
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Introduction
The diagnosis of candidaemia has remained difﬁcult despite
the development of new diagnostic tools. Blood culture has
long been the reference standard, but several autopsy studies
have shown that a number of cases go undiagnosed despite
the use of conventional blood culture [1,2]. Therefore, a
number of alternative diagnostic approaches have been
developed and evaluated over recent decades, including
blood culture systems especially designed for the detection
of fungi, i.e. the Isolator 10 lysis centrifugation system and
bottles with special fungal medium, PCR, antigen (Ag) detec-
tion, mannan and anti-mannan antibody (Ab) detection, and
metabolite detection [1,3–10].
Several theories have been suggested for the lack of sensi-
tivity of blood culture: for example, intermittent presence of
Candida in the blood stream, uptake of Candida in circulating
leucocytes and monocytes or low Candida cell count per mL
of blood. The Isolator 10 lysis centrifugation system exploits
the possibility that white blood cell lysis releases viable
Candida [1]. This technique has proved superior in several
studies [11,12]. The development of blood culture bottles
with medium adjusted for yeast growth has also improved
the detection of Candida, C. glabrata especially [3]. A PCR-
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based system would allow detection of low amounts of
DNA and non-culturable Candida, but as yet only one is
available commercially (SeptiFast; Roche, Basel, Switzerland),
and this is expensive and not thoroughly evaluated. The
Candida-speciﬁc metabolite D-arabinitol (DA) has been used
as a surrogate marker of invasive candidiasis through the
DA/LA (D-arabinitol/L-arabinitol) ratio in urine or serum, or
the DA/creatinine ratio in serum. DA analyses have proven
more sensitive than blood cultures in prospective studies of
children and adults with cancer and neutropenia [13,14]
and in premature newborns [6], but less sensitive in non-
neutropenic postoperative patients [15]. However, a retro-
spective study concluded that serum DA/creatinine ratios
were useful diagnostic and prognostic tests of candidaemia in
patients with a broad range of underlying diseases [16].
Finally, results from antigen and antibody tests indicate that
the latex agglutination format may not be optimal [8,9,17],
with the use of mannan Ag and Ab detection appearing more
promising [18,19]. We present the results of a direct com-
parison of three different blood culture systems, serum DA/
LA ratio, two different antigen tests, and antibody detection.
Materials and Methods
Patients
From June 1997 to January 2000, patients with either (i)
underlying haematological disease and fever not responding
to antibacterial treatment, or (ii) documented systemic Can-
dida infection without disease haematological, were enrolled
prospectively. A form was provided to gather information
on all patients. Clinical information requested included: the
patient’s age and sex; underlying conditions and hospital
department at the time of the positive blood culture; prior
diagnosis of an invasive fungal infection, and if so, the iden-
tity of the fungal agent; criteria for enrolment; the sus-
pected focus of infection and any imaging ﬁndings;
temperature; granulocyte count; the presence of an
indwelling catheter, and whether the patient was receiving
bone marrow transplantation, immunosuppressive or corti-
costeroid therapy. Finally, any other infections documented
were noted, as well as any antibacterial or antifungal ther-
apy given in the 2 weeks before or after enrolment to the
study. Outcome parameters, including time to deferves-
cence, regression of signs and symptoms, and survival were
noted.
Patients were classiﬁed according to the following criteria:
(i) proven invasive Candida infection: (a) positive blood cul-
ture or (b) positive culture or histology from a normally
sterile body site or tissue obtained using a sterile procedure;
(ii) probable invasive Candida infection: fungal colonization
and (a) Candida found in the urine and/or in BAL (if direct
microscopy revealed yeast) and/or (b) response to antifungal
treatment; (iii) possible invasive Candida infection: coloniza-
tion without fulﬁlling the criteria above; (iv) unlikely: no
fungal colonization.
The following samples were taken on day 0: conventional
blood culture (two aerobic and two anaerobic bottles, Col-
orbact, SSI Diagnostika, Hillerød, Denmark from June 1997
to December 1997; and BACTEC, Becton Dickinson, Frank-
lin Lakes, NJ, USA from January 1998 to January 2000); a
fungal blood culture (Mycosis bottle, BACTEC, Becton Dick-
inson); an Isolator 10 lysis centrifugation blood sample (Isola-
tor 10, Wampole, Oxoid Limited, Basingstoke, UK); a serum
sample for antigen, antibody, and DA/LA ratio determination;
a urine sample for culture; surveillance cultures from the
oropharynx and faeces. Follow-up serum samples were
obtained on days 7 and 14, when feasible, for subsequent
antigen, antibody, and DA/LA analysis. Conventional blood
cultures were incubated for 6 days and then sub-cultured on
sabouraud agar for 2 weeks. Mycosis bottles were cultured
for 2 weeks and then sub-cultured on sabouraud agars for a
further 2 weeks. The Isolator 10 Lysis Centrifugation sam-
ples were centrifuged and the pellet inoculated on sabouraud
and Danish blood agars as recommended by the manufac-
turer and cultured for 2 weeks.
Species identiﬁcation
Species identiﬁcation was based on colony morphology on
chromogenic agar (CHROMagar CO., Paris, France), micro-
scopic morphology on corn meal agar and rice plus Tween
agar (SSI Diagnostika), germ tube test and by use of a com-
mercial system (ATB ID20C; bioMe´rieux, Marcy l’Etoile,
France).
D-arabinitol/L-arabinitol ratio determinations
The DA/LA ratio in serum was determined by GC-MS as
previously described for urine [5], using 10 lL serum. Urine
and serum DA/LA ratios are equal (unpublished data) and
the cut-off level for serum DA/LA ratio was set at 4.0, based
on a previous study of adult neutropenic haematological
patients not given empiric antifungal therapy, where the
mean ± SD urine DA/LA ratio was 2.0 ± 1.0 [20].
Antigen and antibody detection
The commercially available CandTec Kit (Ramco Laborato-
ries Inc., Vernn, Houston, TX, USA) was used as recom-
mended by the manufacturer. Agglutination at a 1:2 dilution
was regarded as positive and a further two-fold dilution was
performed and assayed. The titre was reported as the high-
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est serum dilution causing agglutination. In addition, mannan
Ag and anti-mannan Ab concentrations were determined
using Platelia Candida Ag and Platelia Candida AB/AC/AK kits
following the manufacturer’s recommendations (Bio-Rad,
Marnes La Coquette, France) and samples with mannan Ag
concentrations >2.5 ng/mL or anti-mannan Ab >20 AU/mL
were further diluted and re-tested to obtain a precise con-
centration.
Results
From a total of 114 episodes in 93 patients, 95 occurred in
patients with underlying haematological disease [acute mye-
loid leukaemia (n = 53), non-Hodgkin’s lymphoma (n = 19),
chronic lymphatic leukaemia (n = 8), multiple myeloma
(n = 7), acute lymphatic leukaemia (n = 6), chronic myeloid
leukaemia (n = 1) and drug-induced myelosuppression
(n = 1)]. The most common non-haematological host factors
were gastrointestinal surgery (11 episodes in 11 patients),
solid tumour (four episodes in four patients), and liver cir-
rhosis/pancreatitis (four episodes in four patients). A central
venous catheter was in place during 79.8% of the episodes.
During all but two episodes the patients were undergoing
antibacterial treatment. The median and range for the dura-
tion of antibacterial treatment in days was: proven cases 9
(0–40), probable cases 11 (0–38), possible cases 7 (2–43)
and unlikely cases 13.5 (2–43). There was no signiﬁcant dif-
ference in duration of antibacterial treatment among the
groups, with the exception of the possible cases and the unli-
kely cases (p 0.0047, Mann–Whitney test). The majority of
episodes occurred in men (60.5%). The mean and median
age was 55 years (range 21–84 years). The overall mortality
was 38.6%, ranging from 50% in episodes with proven candi-
diasis to 35–38% in episodes classiﬁed in the probable, possi-
ble or unlikely infection groups.
One or more blood culture systems detected Candida
spp. in 24/114 cases (Table 1). In 22/24 episodes the conven-
tional blood cultures grew Candida spp. [C. albicans 17 (one
of which was positive before sampling for the project but
negative in samples taken simultaneously with arabinitol, anti-
body and Ag samples), C. albicans + C. glabrata three, C. tropi-
calis one, and yeast one (seen in direct microscopy from
blood culture but negative on sub-culture and by mycosis
bottle and Isolator 10 system)]. One of these episodes was
not detected by the mycosis bottle. Two episodes were only
positive using the mycosis bottle cultures (both C. albicans).
In one case only subculture from the Isolator tube yielded a
single colony of C. valida, which was considered to be con-
tamination as no clinical signs of fungal infection or coloniza-
tion were found. There were 18 non-haematological patients
with candidaemia; therefore 6/94 (6.4%) haematological
patients had a positive fungal blood culture (Table 2).
The results from antigen, antibody and DA/LA analysis
were not available to the clinicians during the study. Thus,
the institution of empirical antifungal therapy was based upon
clinical parameters and surveillance fungal cultures when
available. Thirty-three patients (28.9%) had received one or
TABLE 1. Blood culture ﬁndings from 114 episodes in 93 patients at risk for candidaemia
Classiﬁcation No.
No. with underlying
haematol. disease Conventional BC Mycosis bottle Isolator 10
Proven 5 2 C. albicans C. albicans C. albicans
1 1 C. albicans Negative Negative
2 0 Negative C. albicans Negative
10 1 C. albicans NDa ND
3 0 C. albicans + C. glabrata ND ND
1 0 C. tropicalis ND ND
1 1 Microscopy pos but
sub-culture negative
Negative Negative
1 1 Prior C. albicans but
negative in project samples
Negative Negative
Blood culture negative 1 1 Negative Negative C. valida (one colony)b
77 77 Negative Negative Negative
7 7 Negative Negative ND
3 3 Negative ND Negative
2 1 Negative ND ND
aND, not done.
bRegarded as contamination.
TABLE 2. Clinical classiﬁcation of the episodes by underly-
ing condition and infection stage
Classiﬁcation
(No.)
Haematological &
neutropenia >2
weeks
Haematological &
no or <2 weeks of
neutropenia
No underlying
haematological
disease
Proven (24) 4 2 18
Probable (14) 10 3 1
Possible (52) 43 8 1
Unlikely (24) 23 1 0
Total (114) 80 14 20
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several antifungal compounds before enrolling in the study,
and empirical antifungal therapy was given to 62 haematologi-
cal patients—12/13 (92.3%) with probable, 35/52 (67.3%) with
possible, and 15/24 (62.5%) with unlikely invasive candidiasis.
The mannan Ag was determined for 110 of the 114
episodes and values are displayed by classiﬁcation in Fig. 1a.
Using the cut-off suggested by the manufacturer (0.25 ng/mL),
12/23 (52.1%) proven episodes were antigen positive, 0/14
(0%) probable episodes, 3/50 (6.0%) possible episodes, and 0/
24 (0%) unlikely episodes. Sensitivity, speciﬁcity, positive (PPV)
and negative predictive values (NPV) are indicated in Table 3.
Lowering the cut-off value to 0.2 or 0.1 ng/mL improves
the performance of the test as one (0.2 ng/mL) or two
(0.1 ng/mL) more proven episodes are detected without the
addition of false positives (Table 3 and Fig. 1a). Follow-up
samples were available for 68 patients (Fig. 1b). All six
patients who were positive for mannan Ag and provided fol-
low-up samples cleared the Ag; ﬁve were undergoing antifun-
gal treatment but one with a possible infection received no
antifungal treatment and had rising anti-mannan Ab levels.
Presence of mannan Ag did not correlate with outcome in
the proven group as mortality was 50% (7/14) in patients
with Ag vs. 5/9 in proven episodes with negative Ag.
Presence of anti-mannan Ab was determined in 112 of the
114 episodes and found in concentrations above the sug-
gested cut-off of 5 AU/mL in 15/24 (62.5%) proven episodes,
8/14 (57.1%) probable episodes, 22/50 (44.0%) possible epi-
sodes and 5/24 (18.3%) unlikely episodes (Fig. 1c). Sensitivity,
speciﬁcity, PPV and NPV are shown in Table 3. By lowering
the cut-off to 4 AU/mL, the positive percentages were 83.3%
(20/24), 64.2% (9/14), 46.0% (23/50) and 25% (6/24), leading
to improved sensitivity, speciﬁcity, PPV and NPV (Table 3).
The proportion of proven episodes positive for anti-mannan
Ab was highest among patients without haematological dis-
ease (Fig. 1c). Follow-up samples are shown in Fig. 1d. Four
of eight patients, with proven infection and for whom
sequential sera were available, had rising Ab levels; three of
these patients survived. No difference was seen in outcome
in anti-mannan Ab-positive and -negative patients with pro-
ven infection (mortality in Ab-negative proven episodes 3/5
vs. 9/19 in Ab-positive patients).
The performance of the combined mannan Ag and
anti-mannan Ab depended on the cut-off chosen (Table 4).
Sensitivity, speciﬁcity, PPV and NPV are shown in Table 5,
using the standard cut-offs and the lower cut-offs suggested
by the data above.
The DA/LA ratio in serum was determined in 110 epi-
sodes (Fig. 1e). Overall, the ﬁrst serum sample was positive
from 10/24 (52%) proven, 3/12 (25%) probable, 9/51 (18%)
possible and 3/22 (14%) unlikely episodes. Sensitivity, speci-
ﬁcity, PPV and NPV are shown in Table 5. Of the patients
with neutropenia and underlying haematological disease, 3/4
were positive with proven disease, 2/9 (22%) with probable
infection, 7/43 (16%) with possible infection and 2/21 (10%)
with unlikely infection (Table 5). Follow-up samples were
available in nine neutropenic haematological patients with
probable (n = 1), possible (n = 6) and unlikely (n = 2) inva-
sive candidiasis receiving empirical antifungal treatment. In all
nine cases initially positive DA/LA ratios normalized during
empiric treatment (Fig. 1f). Antigen tests, however, remained
negative in these patients, whereas two were anti-mannan
Ab positive.
The Latex agglutination test for Candida antigen was per-
formed for all initial sera (Fig. 1g). Sixteen of 24 (66.7%) pro-
ven episodes were positive, 5/14 (35.7%) probable episodes,
12/52 (23.1%) possible and 7/24 (29.1%) unlikely episodes
yielding sensitivity, speciﬁcity, PPV and NPV values as shown
in Table 5. Values of follow-up samples are shown in Fig. 1h.
Discussion
The reference standard for diagnosing invasive candidiasis
is still based on positive blood cultures or positive tissue
FIG. 1. Surrogate markers by underlying disease and candidiasis classiﬁcation (proven, probable, possible, and unlikely). (a) Mannan antigen level
(ng/mL) in ﬁrst serum sample per episode. Horizontal solid line indicates the cut-off value of 0.25 ng/mL recommended by the manufacturer.
Dotted horizontal lines indicate experimental lower cut-off values of 0.2 and 0.1 ng/mL. (b) Mannan Ag level in ﬁrst, second and third serum
sample. Horizontal lines as in Fig 1a. (c) Anti-mannan antibody level (AU/mL) in ﬁrst serum sample per episode. Horizontal solid line indicates
the cut-off value of 5 AU/mL recommended by the manufacturer. Dotted horizontal lines indicate experimental lower cut-off value of 4 AU/mL.
(d) Anti-mannan antibody level (AU/mL) in ﬁrst, second and third serum sample. Horizontal lines as in Fig 1c. (e) DA/LA ratio in ﬁrst serum
sample per episode. Horizontal solid line indicates the cut-off value of 4. (f) DA/LA ratio in ﬁrst, second and third serum sample. Horizontal lines
as in Fig 1e. (g) Candida antigen titre in ﬁrst serum sample per episode determined by CandTec latex agglutination. Titres presented are indi-
cated as highest dilution of serum that leads to agglutination. Titres of ‡2 are regarded as positive. (h) Candida antigen titre in ﬁrst, second and
third serum sample. Titres of ‡2 are regarded as positive. Pen-Haem: Episode in a neutropenic patient with haematological underlying disease.
Haem, episode in a patient with underlying haematological underlying disease but without or less than 2 weeks of neutropenia; Non-Haem, epi-
sode in a patient with no underlying haematological disease.
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cultures; however, the latter are rarely available [2,21]. The
insufﬁcient sensitivity of blood cultures is well known, and
there is a need for complementary diagnostic tests [1]. In
this study we evaluated three blood culture systems, and
four indirect tests: the serum DA/LA ratio, the CandTec
antigen latex agglutination test, Candida mannan Ag and anti-
mannan Ab ELISA tests.
The mycosis bottle appears advantageous when compared
with conventional blood culture systems as two of ten epi-
sodes of proven candidiasis were detected only by mycosis
bottle and in two of ﬁve cases where Candida grew in all
three blood culture systems the mycosis bottle was positive
1–2 days earlier than with the conventional system. This sup-
ports previous ﬁndings that some Candida spp. grow better
in BACTEC mycosis bottles [3]. Only on one occasion was
the candidaemia detected solely by the conventional system;
the conventional system was never the earliest to give a
positive result.
In contrast to earlier reports [12], subculture of the con-
ventional or mycosis bottles did not lead to detection of any
cases above those found by routine incubation of culture
bottles; the Isolator 10 system did not detect any cases
above those detected by the conventional system. This might
result from improved conventional blood culture systems.
The combined use of mannan Ag and anti-mannan Ab detec-
tion performed well, in agreement with previous studies [19],
and we found it to be superior overall to serum DA/LA ratio
determination and Candida antigen detection determined by
CandTec Latex agglutination. The sensitivity and NPV were
increased to 100% by lowering the cut-off values for mannan
Ag and anti-mannan Ab, thereby allowing identiﬁcation of
patients who might beneﬁt from antifungal treatment, as well
as identifying those for whom antifungals are not required. In
our study, however, all sera were frozen prior to testing,
which may have led to a slight lowering of concentrations.
Further studies, using non-frozen samples, are therefore
needed to determine which cut-off values are optimal.
It has previously been shown that arabinitol tests are
highly sensitive (83–100%) in conﬁrmed blood culture-posi-
tive invasive candidiasis in neutropenic cancer patients,
whereas the sensitivity is considerably lower in non-neu-
TABLE 3. Sensitivity, speciﬁcity, positive and negative pre-
dictive values of the mannan antigen and anti-mannan anti-
bodies individually based on the number of positive and
negative test results in the proven and unlikely groups
Sensitivity
(%)
Speciﬁcity
(%)
Positive
predictive
value (%)
Negative
predictive
value (%)
Mannan Ag
0.25 ng/mL as cut-off 52.1 100 100 68.6
0.1 ng/mL as cut-off 60.9 100 100 72.7
Anti-mannan Ab
5.0 AU/mL as cut-off 62.5 79.2 75.0 67.9
4.0 AU/mL as cut-off 83.3 75.0 76.9 81.8
TABLE 4. Number of episodes positive for mannan Ag and/or anti-mannan Ab in the ﬁrst sample indicated by clinical
classiﬁcation and underlying condition using three different combinations of cut-off values
Mannan Ag
& anti-mannan
Ab
Proven Probable Possible Unlikely
Haem
Neutro
penia Haem
Non-
Haem
In
total
Haem
Neutro
penia Haem Non-Haem
In
total
Haem
Neutro
penia Haem
Non-
Haem
In
total
Haem
Neutro
penia Haem
In
total
Cut-off
Ag: 0.25 ng/mL
Ab: 5 AU/mL
4/4 1/2
15/18;
83%
20/24;
83%
6/8 0/3 1/1
7/12;
58%
18/41;
44%
3/8 1/1
22/50;
44%
5/22;
23%
0/1
5/23;
22%
Ag: 0.20 ng/mL
Ab: 4 AU/mL
4/4 1/2
18/18;
100%
23/24;
96%
6/8 1/3 1/1
8/12;
67%
20/41;
49%
3/8 1/1
24/50;
48%
6/22;
27%
0/1
6/23;
26%
Ag: 0.10 ng/mL
Ab: 4 AU/mL
4/4 2/2
18/18;
100%
24/24;
100%
6/8 1/3 1/1
8/12;
67%
20/41;
49%
3/8 1/1
24/50;
48%
6/22;
27%
0/1
6/23;
26%
TABLE 5. Sensitivity, speciﬁcity, positive and negative predictive values (95% conﬁdence intervals given in parentheses) of the
different diagnostic tests based on the number of positive and negative test results in the proven and unlikely groups
Sensitivity Speciﬁcity
Positive
predictive value
Negative
predictive value
Likelihood
ratio
Mannan Ag + anti-Mannan Ab 83.3% (62.6–95.3%) 78.3% (56.3–92.5%) 80.0% (59.3–93.2%) 81.8% (59.7–94.8%) 3.833
Mannan Ag + anti-Mannan Ab using lower cut-offsa 100% (85.7–100%) 73.9% (51.6–89.8%) 80.0% 61.6–92.3%) 100% (80.5–100%) 3.833
DA/LA ratio in serum all patients 41.7% (22.1–63.3%) 86.4% 65.1–97.1%) 76.9% (46.2–95.0%) 57.6% (39.2–74.6%) 3.056
DA/LA ratio in serum, neutropenic patients only 75.0% (19.4–99.4%) 90.5% (69.6–98.8%) 60% (14.7–94.7%) 95% (75.1–99.9%) 7.875
CandTec Candida Ag Latex agglutination 66.6% (44.7–84.4%) 70.8% (48.9–87.4%) 69.6% (47.1–85.0%) 68.0% (46.5–85.0%) 2.286
aAg: 0.10 ng/mL; Ab: 4 AU/mL.
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tropenic patients with candidaemia [13–15]. Moreover,
arabinitol ratios were increased in 52–68% of neutropenic
patients with cancer undergoing empiric antifungal therapy
[13,14]. This has been interpreted to result from an increas-
ing fungal load during long-lasting neutropenia, and arabinitol
tests have accordingly been found to be positive 1–2 weeks
before ﬁrst positive blood culture or onset of empiric ther-
apy [13,14]. These observations are conﬁrmed here, where
3/4 neutropenic haematological candidaemia patients showed
increased DA/LA ratios in contrast to only 0/2 non-neu-
tropenic haematological patients and 7/18 non-haematological
patients with invasive candidiasis. In nine neutropenic haema-
tological patients with non-proven invasive candidiasis (based
on blood cultures), DA/LA ratios initially increased and then
normalized during empiric antifungal treatment. Whether this
indicates invasive candidiasis or a false-positive result cannot
be determined at present. It is difﬁcult to evaluate response
to antifungal treatment, part of the deﬁnition of probable
infection, as these patients often receive multiple treatments
including broad-spectrum antibacterials and corticosteroids.
In this study, C. albicans was by far the most common Can-
dida sp. It should be noted, however, that D-arabinitol is not
produced by C. krusei, nor by C. glabrata, at least in vitro. In a
clinical setting, where C. krusei is more common, the sensitiv-
ity of DA/LA analyses will decrease [20].
In conclusion, in patients with haematological malignancies
and neutropenia, repeated blood cultures, mannan Ag, and
DA/LA monitoring are the preferred tests to diagnose inva-
sive candidiasis. In the non-haematological setting, however,
the combined use of mannan Ag and anti-mannan Ab may be
useful, whereas the DA/LA ratio lacks sufﬁcient sensitivity.
In both patient groups CandTec antigen tests add little
additional information.
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